TIDMMEDG TIDMMEDU

RNS Number : 7524D

Medgenics Inc

01 May 2013

 
 Press Release   1 May 2013

Medgenics Announces Results of 2013 Annual Meeting of Stockholders

Medgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG) (the "Company"), the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announces that all resolutions proposed at the Company's Annual Meeting of Stockholders held yesterday were duly passed.

Each of the current directors of the Company, Dr. Sol J. Barer, Dr. Eugene A. Bauer, Mr. Isaac Blech, Dr. Alastair Clemow, Mr. Joseph J. Grano, Jr., Mr. Joel S. Kanter, Dr. Stephen D. McMurray and Dr. Andrew L. Pearlman, was reelected to the Board of Directors.

Stockholders also approved an amendment of the Company's Stock Incentive Plan, increasing the number of shares authorized to be issued under the plan by 1,700,000 shares.

Stockholders also approved, on an advisory basis, the compensation of the executive officers of the Company. Additionally, the option to request the stockholders to vote, on an advisory basis, on executive compensation every three years received the most votes cast.

Stockholders also ratified the appointment of Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, to serve as the Company's independent registered public accounting firm for the year ended December 31, 2013.

Final voting tallies are subject to certification by the Company's inspector of elections and will be included in the Company's report, which is to be filed with the Securities and Exchange Commission within the next week.

About Medgenics

Medgenics is developing and commercializing Biopump(TM), a proprietary tissue-based platform technology for the sustained production and delivery of therapeutic proteins using the patient's own skin biopsy for the treatment of a range of chronic diseases including anemia, hepatitis C and hemophilia.

For further information, contact:

 
      Medgenics, Inc.                    Phone: +972 4 902 8900 
       Dr. Andrew L. Pearlman 
       andrew.pearlman@medgenics.com 
 
       LHA                                Phone: 212-838-3777 
       Anne Marie Fields 
       afields@lhai.com 
       @LHA_IR_PR 
      Abchurch Communications            Phone: +44 207 398 7719 
       Adam Michael 
       Joanne Shears 
       Jamie Hooper 
       jamie.hooper@abchurch-group.com 
      Nomura Code Securities (NOMAD &          Phone: +44 207 776 1200 
       Joint Broker) 
       Jonathan Senior/Giles Balleny 
       +44 207 776 1200 
      SVS Securities plc (Joint Broker)  Phone: +44 207 638 5600 
       Alex Brearley

- Ends -

This information is provided by RNS

The company news service from the London Stock Exchange

END

ROMEAFSFEAPDEFF

Medgenics(Regs) (LSE:MEDG)
Gráfica de Acción Histórica
De May 2024 a Jun 2024 Haga Click aquí para más Gráficas Medgenics(Regs).
Medgenics(Regs) (LSE:MEDG)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024 Haga Click aquí para más Gráficas Medgenics(Regs).